

Resource Summary Report

Generated by [RRID](#) on Sep 4, 2026

4T1-Luc2 [ATCC]

RRID:CVCL_A4BM

Type: Cell Line

Proper Citation

RRID:CVCL_A4BM

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_A4BM

Proper Citation: RRID:CVCL_A4BM

Description: Cell line 4T1-Luc2 [ATCC] is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Malignant neoplasms of the mouse mammary gland

Comments: Characteristics: Stably expresses firefly luciferase under the control of the human EF1a promoter (ATCC=CRL-2539-LUC2).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: 4T1-Luc2 [ATCC]

Cross References: ATCC:CRL-2539-LUC2, Wikidata:Q105505946

ID: CVCL_A4BM

Hierarchy: cvcl_0125

Record Creation Time: 20220427T215055+0000

Record Last Update: 20260904T021113+0000

Ratings and Alerts

No rating or validation information has been found for 4T1-Luc2 [ATCC].

No alerts have been found for 4T1-Luc2 [ATCC].

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Hu M, et al. (2026) Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity. *Cancer cell*, 44(5), 965.

Nguyen TQA, et al. (2026) Targeting RNase H2: A dual-mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in TNBC. *Cell reports. Medicine*, 7(5), 102750.

Pei Z, et al. (2026) STAT3 interference-driven nanomodulators reverse lipid metabolism-associated chemoresistance and potentiate metalloimmunotherapy in breast cancer. *Cell reports. Medicine*, 7(6), 102844.

Qu C, et al. (2026) Targeted extracellular vesicle-photoimmunotherapy remodels stromal-immune microenvironment to boost chemo-immunotherapy in preclinical models. *Cell reports. Medicine*, 7(7), 102843.

Sun M, et al. (2026) Intracellular sclerostin promotes tumor progression and metastasis as a potential therapeutic target in triple-negative breast cancer. *Cell reports. Medicine*, 7(5), 102763.

Fan G, et al. (2026) Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways. *Cancer cell*, 44(6), 1160.

Ermogenous C, et al. (2026) MIF mediates monocyte-dependent inhibition of natural killer cell cytotoxicity in triple-negative breast cancer. *Cell reports*, 45(6), 117431.

Zhang J, et al. (2025) Enabling tumor-specific drug delivery by targeting the Warburg effect of cancer. *Cell reports. Medicine*, 6(1), 101920.

Gu Y, et al. (2025) Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization. *Angiogenesis*, 28(2), 13.

Koltun B, et al. (2025) Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug Resistance. *Molecular cancer therapeutics*, 24(11), 1815.

Laplante P, et al. (2025) Effect of MisMatch repair deficiency on metastasis occurrence in a syngeneic mouse model. *Neoplasia (New York, N.Y.)*, 62, 101145.

Zhang Y, et al. (2024) Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer. *Cell metabolism*, 36(1), 193.

Wang Z, et al. (2023) Isolation of tumour-reactive lymphocytes from peripheral blood via microfluidic immunomagnetic cell sorting. *Nature biomedical engineering*, 7(9), 1188.

Beziau L, et al. (2023) IFN γ -induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy. *Cell stem cell*, 30(6), 818.

Amano T, et al. (2023) Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity. *iScience*, 26(4), 106335.

Shen JZ, et al. (2022) A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells. *Molecular cell*, 82(6), 1123.